65,437 trials
Healthy
Primary: Cmax for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together) — 1.03; 1.39; 2.96; 2.95 ng/mL
Lennox-Gastaut Syndrome
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Rufinamide — 54; 38; 9; 2 Participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.95; -0.65 Percentage of HbA1c — p=<0.0001
Benign Prostatic Hypertrophy Requiring Surgical Intervention
Primary: Morcellation Rate — 4.8; 5.6 grams/minute
Obstructive Sleep Apnea
Primary: Rescue Morphine Requirement — 30 mg
Cardiotoxicity
Primary: Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.493; 5.229 milliseconds
Herpes Zoster
Primary: Geometric Mean Fold Rise (GMFR) of the VZV-specific Immune Responses Measured by VZV Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISPOT) — 4.34 Ratio — p=<0.001
Peptic Ulcer
Primary: Number of Participants With Healed Peptic Ulcer — 106; 101 participants
Healthy
Primary: The Largest Treatment Difference (Loxapine - Placebo) in Change in FEV1 From Baseline by Spirometry — -0.1042; -0.1025 liters
HIV Infection
Primary: Magnitude of Change (Fold Change) in Parathyroid Hormone (PTH) From Baseline to Week 48 — 1.08 fold change
Sickle Cell Disease
Primary: Number of Participants Who Completed Follow up — 35; 17 Participants
Recurrent Acute Rhinosinusitis
Primary: CSS Total Score Change From Baseline to 24 Week Visit — 37.3; 21.8 scores on a scale
Contraception
Primary: Number of Participants Reporting IUC Use — 2; 4 Participants — p=0.89
Corneal Endothelial Cell Loss
Primary: Center Method Corneal Endothelial Cell Density — 3069.5; 2678.6; 2514 cells/mm2
Chronic Functional Diarrhea of Unknown Origin
Primary: Mean Change From Baseline in Blood Lead Levels During the Treatment Period and Post-treatment Follow-up Period — 0.120; 0.306; 0.095; 0.359 nanograms per millilitre…